People who are hungry gut-positive have normal responses to hormone signaling in the brain, the researchers said. Meanwhile, ...

Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.

Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth ...

Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital and existing investors aMoon Fund and Blackstone Multi-Asset ...

According to AltruBio, the new lead prospect has shown improved potency in down-regulating chronic pathogenic T cells in ...

About 4 in 10 people who use GLP-1 agonist drugs do so mainly for weight loss, not to treat diabetes, a new study finds.

Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ...

The European Renal Association (ERA) kicks off its 61 st ERA Congress in Stockholm, Sweden, with a theme of "Rethinking kidney health, transforming kidney care," and a program full of sessions delving ...

For the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes, have struggled to fill their prescriptions for the medications they need to control their blood ...

Hundreds linked up to have their picture taken with Will Flanary, M.D., an ophthalmlogist in Portland, Oregon, and a hugely ...

Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight ...

Vicore Pharma announces positive results from phase 2a AIR trial of buloxibutid in idiopathic pulmonary fibrosis: Stockholm Tuesday, May 21, 2024, 12:00 Hrs [IST] Vicore Pharma Ho ...